Search results

  • Full text

  • Document type

    • Publication year

  • Organisation

Results: 32
Number of items: 32
  • Open Access
    Verstegen, N. J. M., Hagen, R. R., Kreher, C., Kuijper, L. H., Dijssel, J. V. D., Ashhurst, T., Kummer, L. Y. L., Palomares Cabeza, V., Steenhuis, M., Duurland, M. C., Jongh, R. D., Schoot, C. E. V. D., Konijn, V. A. L., Mul, E., Kedzierska, K., van Dam, K. P. J., Stalman, E. W., Boekel, L., Wolbink, G., ... T2B! immunity against SARS-CoV-2 study group (2024). T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination. Journal of Neurology, Neurosurgery and Psychiatry, 95(9), 855–864. https://doi.org/10.1136/jnnp-2023-332224
  • van Dam, K. P. J., Takkenberg, R. B., Bemelman, F. J., de Wit, J., Busch, M. H., Verstegen, N. J. M., van Ham, S. M., Tas, S. W., & T2B! immunity against SARS-CoV-2 study group (2023). Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations. Journal of autoimmunity, 135, Article 102984. https://doi.org/10.1016/j.jaut.2022.102984
  • Open Access
    van Dam, K. P. J., Tas, S. W., Takkenberg, R. B., Bemelman, F. J., de Wit, J., Busch, M. H., Verstegen, N. J. M., van Ham, S. M., & T2B! immunity against SARS-CoV-2 study group (2023). Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity. BMC Infectious Diseases, 23, Article 332. https://doi.org/10.1186/s12879-023-08298-6
  • Open Access
    Musters, A. (2023). Towards targeting of adaptive immune responses in rheumatoid arthritis. [Thesis, fully internal, Universiteit van Amsterdam].
  • Open Access
    Mol, S. (2023). Neutrophil activation in disease: An unexpected journey. [Thesis, fully internal, Universiteit van Amsterdam].
  • Stalman, E. W., Tas, S. W., Takkenberg, R. B., Bemelman, F. J., de Wit, J., Verstegen, N. J. M., van Ham, S. M., & T2B! immunity against SARS-CoV-2 study group (2022). Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases. Annals of the Rheumatic Diseases, 81(12), 1757-1766. https://doi.org/10.1136/ard-2022-222904
  • Boekel, L., Besten, Y. R., Hooijberg, F., Wartena, R., Steenhuis, M., Vogelzang, E., Leeuw, M., Atiqi, S., Tas, S. W., Lems, W. F., van Ham, S. M., Eftimov, F., Stalman, E. W., Wieske, L., Kuijpers, T. W., Voskuyl, A. E., van Vollenhoven, R. F., Gerritsen, M., Krieckaert, C., ... Wolbink, G. (2022). SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period. The Lancet. Rheumatology, 4(11), e747-e750. https://doi.org/10.1016/S2665-9913(22)00221-1
  • Boekel, L., Tas, S. W., Takkenberg, R. B., Bemelman, F. J., de Wit, J., Verstegen, N. J. M., van Ham, S. M., & T2B! immunity against SARS-CoV-2 study group (2022). Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies. The Lancet. Rheumatology, 4(6), e417-e429. https://doi.org/10.1016/S2665-9913(22)00102-3
  • Wieske, L., Tas, S. W., Takkenberg, R. B., Verstegen, N. J. M., Zwinderman, K. A. H., van Ham, S. M., & T2B! immunity against SARS-CoV-2 study group (2022). Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study. The Lancet. Rheumatology, 4(5), e338-e350. https://doi.org/10.1016/S2665-9913(22)00034-0
  • Open Access
    Wieske, L., Takkenberg, R. B., Tas, S. W., Bemelman, F. J., ten Brinke, A., Verstegen, N. J. M., van Ham, S. M., & T2B! immunity against SARS-CoV-2 study group (2022). Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases. BMC Medicine, 20, Article 100. https://doi.org/10.1186/s12916-022-02310-7
Page 2 of 4